Klacid (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This blocks the translocation step of peptide chain formation, halting bacterial growth (bacteriostatic) and, at higher concentrations, killing the organisms (bactericidal).

The dose of Klacid is determined by the prescribing clinician based on the infection being treated, patient weight, renal and hepatic function, and local guidelines. Exact dosing regimens are not disclosed here.

Clarithromycin is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk. Use while breastfeeding should be discussed with a healthcare professional.

To order Klacid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Klacid belongs to the macrolide class, similar to azithromycin. Compared with azithromycin, clarithromycin often provides a broader spectrum against certain Gram‑positive organisms and has a higher intracellular concentration, but it may have a greater potential for drug‑drug interactions due to CYP3A4 inhibition.

Klacid should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture, and extreme temperatures. Do not freeze. Follow standard aseptic techniques when preparing for intravenous administration.

Klacid is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period recommended by the prescriber, often 30 minutes to 2 hours, depending on the clinical situation and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, hepatic dysfunction, QT‑interval prolongation leading to arrhythmias, Clostridioides difficile‑associated colitis, and rare hematologic abnormalities like neutropenia.

Klacid should not be used in patients with known hypersensitivity to clarithromycin or other macrolides, those with significant QT prolongation, severe hepatic impairment, or in combination with drugs that have contraindicated interactions such as cisapride or pimozide.